Mohit Bansal
Stock Analyst at Wells Fargo
(4.09)
# 431
Out of 4,959 analysts
165
Total ratings
61.05%
Success rate
9.27%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $395.12 | +16.42% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $110.88 | +35.28% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $87.37 | +3.01% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $589.48 | -1.61% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $38.84 | +21.01% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $71.82 | -9.50% | 7 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $62 → $53 | $47.92 | +10.60% | 9 | Apr 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $1.27 | -21.26% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $711.68 | +54.56% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $114.77 | +21.98% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $240 | $210.60 | +13.96% | 8 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $139.31 | +0.50% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $123.11 | +38.09% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $293.72 | -4.67% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $26.20 | +14.50% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $22.57 | +210.15% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $17.92 | +50.67% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $58.58 | +53.64% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.88 | +15.92% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $135.43 | +25.53% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.89 | +81.39% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $11.43 | +16,304.20% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.96 | +3,650.00% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $13.27 | +43.18% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.06 | +8,687.35% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.17 | +5,028.21% | 4 | Dec 3, 2019 |
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $395.12
Upside: +16.42%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $110.88
Upside: +35.28%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $87.37
Upside: +3.01%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $589.48
Upside: -1.61%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $38.84
Upside: +21.01%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $71.82
Upside: -9.50%
Bristol-Myers Squibb Company
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $47.92
Upside: +10.60%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.27
Upside: -21.26%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $711.68
Upside: +54.56%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $114.77
Upside: +21.98%
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $210.60
Upside: +13.96%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $139.31
Upside: +0.50%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $123.11
Upside: +38.09%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $293.72
Upside: -4.67%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $26.20
Upside: +14.50%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $22.57
Upside: +210.15%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $17.92
Upside: +50.67%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $58.58
Upside: +53.64%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.88
Upside: +15.92%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $135.43
Upside: +25.53%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $14.89
Upside: +81.39%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $11.43
Upside: +16,304.20%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.96
Upside: +3,650.00%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $13.27
Upside: +43.18%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.06
Upside: +8,687.35%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.17
Upside: +5,028.21%